ClinicalTrials.gg
CompletedNCT01364857CONAPEUpdated Dec 22, 2025

French National Cohort of Children With Port Wine Stain

An interventional study of search for polymorphisms of RASA1 gene in Port Wine Stain, Klippel Trenaunay Syndrome and Parkes Weber Syndrome, sponsored by University Hospital, Tours. Completed at 17 sites in France. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by University Hospital, Tours · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2010, registered May 2011).
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
2 Years to 12 Years
Sex
All
01

Study summary

Port Wine Stain on a limb can be either isolated or associated with complications (venous or orthopedic impairment, arteriovenous malformations), leading sometimes to complex syndromes (Klippel-Trenaunay syndrome,Parkes-Weber syndrome).

Little is known about epidemiology of port wine stains: their evolution during the growth of the child, the frequency of complications, genetic data, and prognostic factors.

This prospective french national cohort will help for : description of the evolution of port wine stain and possible complications; prognostic factors for complications ; association with mutations of RASA1 gene; quality of life of these children. It will also help for global appreciation of the management of this disease in France.

Read the detailed description

Prospective national study, including 16 Pediatric and Dermatologic Departments.

Methods : each children with a port wine stain on a lower limb will be followed up for 5 years.

Collected data : demographic data, clinical features, alterations of RASA1 gene, vascular evaluation by ultrasonographic and orthopedic evaluation by X rays, quality of life with a questionnaire.

Inclusion period = 3 years Follow up period = 5 years Population = 150 children

02

Conditions studied

  • Port Wine Stain
  • Klippel Trenaunay Syndrome
  • Parkes Weber Syndrome

Keywords

  • port wine stain of a limb
03

In context

Port-Wine Stain

45 studies on the registry are indexed under Port-Wine Stain; 7 are open to participants now.

This study's enrollment of 150 is above the median of 29 across 30 interventional studies indexed under Port-Wine Stain.

Browse Port-Wine Stain studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 307 studies on the registry; 79 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child between 2 and 12 years old with a port wine stain on a lower limb ( or two lower limbs) with national health assurance with consent from one parent

Exclusion criteria

Exclusion Criteria:

  • child with orthopedic impairment with no link with the port wine stain
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Other
    PWS cohort

    search for polymorphisms of RASA1 gene

    Genetic: search for polymorphisms of RASA1 gene

Interventions

  • Geneticsearch for polymorphisms of RASA1 gene

    Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent

06

What researchers measure

Primary outcomes

  1. Complicated evolution (defined as: vascular, orthopedic or systemic involvement linked with the port wine stain)

    Complicated evolution (defined as: vascular, orthopedic or systemic involvement linked with the port wine stain)

    Time frame: during the 5 years of follow up

Secondary outcomes

  1. Mutations of RASA 1 gene

    Mutations of RASA 1 gene

    Time frame: during the 5 years of follow up

07

Study locations

17 sites
  • Service de dermatologie
    Amiens, 80054, France
  • Service de dermatologie
    Angers, 49933, France
  • Service de dermatologie
    Bordeaux, 33000, France
  • Service de dermatologie
    Caen, 14033, France
  • Service de dermatologie
    Dijon, 21079, France
  • Service de Dermatologie, Bâtiment tardieu
    Le Mans, 72037, France
  • Service de Dermatologie, Hôpital St Eloi
    Montpellier, 34295, France
  • Service de dermatologie
    Nantes, 44093, France
  • Service de dermatologie
    Nice, 06202, France
  • Service de dermatologie
    Paris, 75743, France
  • Service de dermatlogie
    Quimper, 29107, France
  • Service de dermatologie
    Reims, 51092, France
  • Service de Dermatologie, Hôpital Pontchaillou, CHU de Rennes
    Rennes, 35033, France
  • Service de dermatologie
    Rouen, 76031, France
  • Service de dermatologie
    Saint-Etienne, 42055, France
  • Service de dermatologie
    Toulouse, 31059, France
  • Service de dermatologie
    Tours, 37044, France
08

References and documents

Publications

  • Maruani A, Durieux-Verde M, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Eschard C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Berthelot A, Lorette G, Leducq S, Samimi M, Andres C, Caille A, Vourc'h P; Groupe de Recherche de la Societe Francaise de Dermatologie. Search for RASA1 Variants in Capillary Malformations of the Legs in 113 Children: Results from the French National Paediatric Cohort CONAPE. Acta Derm Venereol. 2018 Feb 7;98(2):251-255. doi: 10.2340/00015555-2835. PubMed 29110021 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2010 to primary completion in Nov 2019, 108 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 3, 2011
StartActual
Nov 2010
Primary completionActual
Nov 2019
CompletionActual
Nov 2019
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01364857
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
Nov 2010
Primary completion
Nov 2019
Completion
Nov 2019
Last update
Dec 22, 2025

Study contacts

Violaine MIZZI
study chair · University Hospital, Tours

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion